Video

Dr. Flaherty on the Significance of the NCI-MATCH Precision Medicine Trial

Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.

Keith T. Flaherty, MD, professor of medicine at Harvard Medical School, as well as the director of the Henri and Belinda Termeer Center for Targeted Therapy, and director of clinical research at the Cancer Center of Massachusetts General Hospital, discusses the significance of the NCI-MATCH study.

NCI-MATCH represents an important milestone in the broad area of public/private collaboration, Flaherty says. The trial was sponsored by the National Cancer Institute (NCI)-sponsored trial and conducted in the National Clinical Trial Network; it was led by ECOG-ACRIN Cancer Research Group, of which Flaherty has been a career-long member, and the NCI. 

Additionally, the universal enthusiastic engagement from pharmaceutical companies was critical to the success of the trial, Flaherty adds. When designing the trial, investigators set out to survey the whole landscape of oncology drug development. They wanted to evaluate any drug that was ready for phase 2 testing, for which there was a strong scientific reason to believe that there is a molecular feature, a genetic alteration or otherwise, that would help to identify patients who would respond to treatment, irrespective of their tumor type, Flaherty concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity